Key result
Four-factor prothrombin complex concentrate mitigated rivaroxaban-induced bleeding in emergent coronary artery bypass grafting, allowing discharge on day 9 without sequelae.
Why the study?
Does four-factor prothrombin complex concentrate mitigate rivaroxaban-induced bleeding in a patient undergoing emergent CABG?
Does four-factor prothrombin complex concentrate mitigate rivaroxaban-induced bleeding in a patient undergoing emergent CABG?
4F-PCC may be a viable option for mitigating rivaroxaban-induced bleeding during emergent CABG when direct antidotes are unavailable.
No takes yet. Share an insight, caveat, or question.
May facilitate emergent CABG on rivaroxaban; leaves open need for prospective trials.
Liu et al. (2017) studied this question. Four-factor prothrombin complex concentrate mitigated rivaroxaban-induced bleeding in emergent coronary artery bypass grafting, allowing discharge on day 9 without sequelae.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: